Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Annalisa, Berselli"'
Autor:
Angela Damato, Francesco Iachetta, Lorenzo Antonuzzo, Guglielmo Nasti, Francesca Bergamo, Roberto Bordonaro, Evaristo Maiello, Alberto Zaniboni, Giuseppe Tonini, Alessandra Romagnani, Annalisa Berselli, Nicola Normanno, Carmine Pinto
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has shown to be one of the therapeutic regimens in first line with the highest activity in patients (pts.) with metastatic colorectal cancer (mCRC)
Externí odkaz:
https://doaj.org/article/9a75853473884e25bfdf6723ee62dbf3
Autor:
Carmine Pinto, Annalisa Berselli, Lucia Mangone, Angela Damato, Francesco Iachetta, Marco Foracchia, Francesca Zanelli, Erika Gervasi, Alessandra Romagnani, Giuseppe Prati, Stefania Lui, Francesco Venturelli, Massimo Vicentini, Giulia Besutti, Rossana De Palma, Paolo Giorgi Rossi
Publikováno v:
Biology, Vol 9, Iss 8, p 181 (2020)
In the coronavirus disease (COVID-19) pandemic, cancer patients could be a high-risk group due to their immunosuppressed status; therefore, data on cancer patients must be available in order to consider the most adequate strategy of care. We carried
Externí odkaz:
https://doaj.org/article/4ed028bf5556494a85420ecd9d062a11
Autor:
Lorenzo Antonuzzo, Carmine Pinto, Guglielmo Nasti, Alessandra Romagnani, Roberto Bordonaro, Francesco Iachetta, Giuseppe Tonini, Evaristo Maiello, Angela Damato, Alberto Zaniboni, Annalisa Berselli, Nicola Normanno, Francesca Bergamo
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer
BMC Cancer
Background FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has shown to be one of the therapeutic regimens in first line with the highest activity in patients (pts.) with metastatic colorectal cancer (mCRC) unselect
Autor:
Gabriele Luppi, G. Rovesti, Carmine Pinto, Annalisa Berselli, Andrea Spallanzani, Angela Damato, S. Benatti
Publikováno v:
Annals of Oncology
Background: Higher incidence of severe events in cancer pts affected by COVID-19 have been reported However, the association with oncological treatments is not clear yet Recommendations have been released by Italian scientific society and colleges (A
Autor:
Giulia Besutti, Francesco Iachetta, Stefania Lui, Erika Gervasi, Giuseppe Prati, Paolo Giorgi Rossi, Angela Damato, Alessandra Romagnani, Annalisa Berselli, Francesco Venturelli, F. Zanelli, Marco Foracchia, Rossana De Palma, Carmine Pinto, Lucia Mangone, Massimo Vicentini
Publikováno v:
Biology, Vol 9, Iss 181, p 181 (2020)
Biology
Volume 9
Issue 8
Biology
Volume 9
Issue 8
In the coronavirus disease (COVID-19) pandemic, cancer patients could be a high-risk group due to their immunosuppressed status
therefore, data on cancer patients must be available in order to consider the most adequate strategy of care. We carr
therefore, data on cancer patients must be available in order to consider the most adequate strategy of care. We carr
Autor:
Lorenzo Antonuzzo, Guglielmo Nasti, Angela Damato, Carmine Pinto, Francesca Bergamo, Annalisa Berselli, Alicia Garcia Arias, Francesco Iachetta, Mario Larocca, Alessandra Romagnani
Publikováno v:
Journal of Clinical Oncology. 39:37-37
37 Background: NIVACOR trial is an open-label, multicentric Italian phase II trial of FOLFOXIRI/bevacizumab in association with an anti-PD1 antibody, nivolumab, in patients (pts) with metastatic colorectal cancer (mCRC). We report preliminary safety
Autor:
M. Tiseo, Frederico Cappuzzo, Giulia Pasello, Carmine Pinto, Francesco Grossi, F. Zanelli, Paolo Pedrazzoli, Giovanni Luca Ceresoli, Candida Bonelli, Federica Grosso, H. Soto Parra, Paolo Andrea Zucali, F. De Marinis, Annalisa Berselli, Nicola Normanno, Maria Pagano, M.C. Garassino
Publikováno v:
Annals of Oncology. 31:S1078
Autor:
Evaristo Maiello, Lorenzo Antonuzzo, Angela Damato, Giuseppe Tonini, Roberto Bordonaro, Annalisa Berselli, Nicola Normanno, Alberto Zaniboni, Carmine Pinto, Francesco Iachetta, Francesca Di Fabio, Alessandra Romagnani, Francesca Bergamo, Guglielmo Nasti
Publikováno v:
Journal of Clinical Oncology. 38:TPS4118-TPS4118
TPS4118 Background: FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has been shown to be one of the therapeutic regimens in first line with the highest activity profile in patients (pts) with metastatic colorectal c
Autor:
Alessio Bruni, Sebastiano Buti, Carmine Pinto, Stefania Kinspergher, Giuseppe Procopio, Franco Morelli, Roberto Salvatore Bellia, Cristina Masini, Cinzia Baldessari, Susanne Baier, Renzo Mazzarotto, Cinzia Iotti, Franco Nolè, Claudia Mucciarini, Ilaria Zampiva, Ugo De Giorgi, Consuelo Buttigliero, Francesco Salaroli, Annalisa Berselli
Publikováno v:
Web of Science
613 Background: NIVO showed an increased on OS in pre-treated mRCC. The introduction of metastasis SBRT could improve the clinical outcomes. NIVES Study evaluated the efficacy and safety of SBRT in combination with NIVO in II and III line of mRCC pts
Autor:
Maria Pagano, Cristina Masini, Elisa Gasparini, Giuseppe Prati, Emanuela Fantinel, Alessandra Romagnani, Erika Gervasi, Annalisa Berselli, Carmine Pinto, Giovanna Stridi, R. Gnoni, Candida Bonelli, G. Moretti, Maria Banzi
Publikováno v:
Journal of Clinical Oncology. 37:e14156-e14156
e14156 Background: Checkpoint inhibitors in cancer therapy have shown survival benefits in the treatment of several ATs. However, the risk of serious side effects seems greater in certain types of tumors presenting reduced compliance with therapy. Th